Bhupendra Khatri

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

Jeffrey A. Cohen, Frederik Barkhof, Hans‐Peter Hartung et al. · New England Journal of Medicine · 2010 · 2.2K citations · Full text

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 327 citations · Full text

Disease Progression, Neurological Disorder, Immunology +8

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

Bhupendra Khatri, S. Man, Gavin Giovannoni et al. · Neurology · 2009 · 276 citations · Full text

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

Bhupendra Khatri, Frederik Barkhof, Giancarlo Comi et al. · The Lancet Neurology · 2011 · 215 citations · Full text

Amyotrophic Lateral Sclerosis, Neurobiology Of Disease, Disease Progression +10